AbbVie Boosts FY23 Outlook As Q2 Results Top Estimates

WASHINGTON (dpa-AFX) – While reporting financial results for the second quarter on Thursday, biopharmaceutical company AbbVie, Inc. (ABBV) trimmed its adjusted earnings guidance for the full-year 2023. For fiscal 2023, AbbVie now projects adjusted earnings in a range of $10.90 to $11.10 per share, which includes an unfavorable impact of…Read More